Switch to:
More From Other Websites
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as... Apr 27 2017
Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space Apr 27 2017
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 Apr 27 2017
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission Apr 26 2017
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017 Apr 25 2017
Tesaro Announces Participation in Two Investor Conferences Apr 25 2017
Tesaro Inc Bulls Need a Reality Check Apr 25 2017
Biotech M&A Plunges as Trump Attacks Drug Companies Apr 24 2017
Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing Apr 21 2017
Tesaro stock dives 7% after drug pricing snafu Apr 21 2017
Tesaro’s Zejula Flops as H&S Pattern Emerges Apr 21 2017
AbbVie's PARP Inhibitor Comes Up Empty Apr 20 2017
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in... Apr 19 2017
3 Stocks With Shopify-Like Return Potential Apr 19 2017
Traders say mergers and acquisitions could bring boost to biotech stocks Apr 13 2017
These 3 Stocks Have Tripled Over the Past Year Apr 13 2017
Tesaro: Good News Is Already Baked Into The Stock Apr 10 2017
Why Clovis Oncology's Stock Edged Higher in March Apr 07 2017
Medidata & TESARO Win CARE 'Clinical Partnership' Award Apr 07 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK